Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets trade strong
Mon, 12 May 01:30 pm

The Indian markets continued to trade at stratospheric levels during the previous two hours of trading session on account of continuous buying activity among the index heavy weights. Except the healthcare sector, all sectoral stocks are trading positive. Buying interest is heavy among the energy and banking sector stocks.

The BSE Sensex is trading up 426 points and the NSE-Nifty is trading up 116 points. The BSE Mid Cap index is trading up 0.7% and the BSE Small Cap index is trading up 0.5% today. The rupee is trading at 59.72 to the US dollar.

Majority of the domestic pharma stocks are trading in the red with Panacea Biotech and Indoco Remedies being the biggest losers. As per a leading financial daily, Cipla has invested $21 m in US-based Chase Pharmaceuticals through its wholly owned subsidiary in UK. Chase Pharmaceuticals is a drug development company focusing on novel treatments for Alzheimer's disease. The investment is to support phase 2a and phase 2b of clinicla trials for Chase's lead drug CPC 201. Additionally, Cipla will also collaborate with Chase for the development of the drug which will be sold by the former as low cost medicine in India and South Africa. This investment is consistent with the company's philosphy of providing affordable medicines and building innovative business streams. Reportedly, five million people in India are suffering from dementia with a majority of them afflicted with Alzheimer's disease. By 2018, these figures are likely to double. Cipla stock is currently trading down 1.7%.

Large capitalization software stocks are trading mixed today. While Infosys and Tech Mahindra are trading higher, Wipro and HCL Infosystems are trading on a weak note. As per a leading business daily, Tech Mahindra plans to consider an acquisition in order to lower its dependence on the telecommunications business. In fact, it may opt for businesses that are focussed on the niche segment. Around 47% of Tech Mahindra's revenues are from the telecom sector.It plans to lower the same and increase its exposure in other sectors like healthcare and retail. A Gartner, the independent research institution on IT sector, expects software spending from telecommunication players to grow by 1.3% this year as compared to spending growth of 4.6% in other industries. So the move is to enable Tech Mahindra of expand its offering and caters to the high growth business verticals and simultaneously lower its concentration to the single segment.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets trade strong". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.